Aptorum Group has joined forces with Covar Pharmaceuticals for studying the use of three repurposed drug candidates for the treatment of novel coronavirus (COVID-19).
Aptorum Group is set to choose at least three repurposed drug candidates for Covid-19 treatment, out of nearly 2,600 approved small drug molecules screened using its Smart-ACT drug discovery platform.